ARK Autonomous Technology & Robotics ETF vs Centene Corp — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $128.4, while Centene Corp trades at $66.33 (market cap $32.89B). The key difference: Centene Corp is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | CNC | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $68.72 |
52-Week Low | $95.28 | $26.17 |
Market Cap | — | $32.89B |
Enterprise Value | — | $21.93B |
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $127.85, up 3.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support and resistance levels indicate key price zones for near-term movement.
The outlook for ARKQ is supported by long-term themes in AI and robotics, though high RSI levels suggest caution. Risks include sector volatility and reliance on disruptive tech stocks. Analyst sentiment is mixed, with some recommending accumulation during dips for growth-oriented investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →